using e-nose technology to identify early lung cancer

Conditions: Lung; Node; Lung Cancer

Summary: the purpose of this study is to test the ability of a new technology called breathprinting, or electronic nose (e-nose), to detect early-stage lung cancer. additionally, researchers also want to see if the e-nose technology is more effective at diagnosing lung cancer if the tumor size is larger.


Eligibility criteria:
inclusion criteria: * age 21-85 * single, monolateral nodule of at least 50% solid composition visible on chest ct scan (with or without contrast) suspicious for lung cancer. * msk radiologist report or read suggestive (i.e. at least 50% certainty) of suspected primary lung cancer (in accordance with the level of certainty criteria set forth by mskcc radiology) o patients with biopsy-proven early stage, primary lung cancer that meets staging requirements, do not need to also have a radiology report meeting inclusion criteria * negative test for covid-19 performed locally or at msk, done as part of standard of care testing (i.e. only when required by specific institutional policy) prior to biopsy or surgical procedure * eligible for fine-needle aspiration biopsy, robotic bronchoscopy, and/or surgical resection for diagnosis (i.e., does not have comorbidities precluding these). * documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study o patient must agree to undergo fine-needle aspiration biopsy, robotic bronchoscopy, and/or surgical resection for diagnosis prior to e-nose collectionnote: biopsy-proven patients that meet eligible staging criteria who are not further surgical candidates will be collected prior to next step in standard of care treatment * patients with biopsy-proven clinical stage i lung cancer are eligible if the biopsy is done within 6 weeks of the consent date exclusion criteria: * age \ 85 years at first outpatient visit. * multiple ipsilateral or bilateral nodules reported on chest ct scan and/or concurrent as suspicious for lung cancer (note: nodules deemed indeterminate, inflammatory, etc. will not exclude a patient from participating in this study) semisolid ggos. * lung nodule of interest is less than 50% solid in composition * per msk radiologist report or read, the lung nodule of interest is "less likely" or "unlikely" (i.e. less than 50% certainty) to be neoplastic (in accordance with the level of certainty criteria set forth by mskcc radiology) * any previous history of lung cancer * history of any non-lung cancer(s) that is currently being treated (note: prior history of completely treated non-lung cancer from any time will be eligible) * metastatic lung cancer disease seen on chest ct or pet scan at hilar/mediastinal nodes or contralateral lung or extrathoracic sites. * previous medical history of a lung biopsy/surgical procedure for cancer diagnosis (note: patients who underwent a lung biopsy over three years ago that showed negative for lung cancer and patients who underwent a lung biopsy confirming stage i lung cancer within the past 6 weeks will be eligible)

Keywords: lung cancer lung nodule lung node memorial sloan kettering caner center 20-349 breathprinting